Major Depressive Disorder Clinical Trial
Official title:
Adjunctive Creatine Treatment for Adolescent Females With Major Depressive Disorder Who Are Non-Responders to Fluoxetine or Escitalopram: A Magnetic Resonance Spectroscopy Study
Verified date | January 2015 |
Source | University of Utah |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study is to see if creatine, which is a naturally occurring chemical in
the body, is effective for treating Major Depressive Disorder (MDD) in female teenagers.
Creatine may have effects of interest in the brain. The reason for the MRI component of this
study is to learn about new ways to see inside the brain. The investigators will use
magnetic fields and radio waves to look at the brain and chemicals in the brain. The
investigators hope that this technique will have medial use in the future.
The primary hypothesis of the study is that oral creatine supplementation will have a
beneficial effect as adjunctive therapy in female adolescents with MDD who are
non-responders to an adequate trial of the SSRIs Fluoxetine or Escitalopram.
Status | Completed |
Enrollment | 13 |
Est. completion date | December 2012 |
Est. primary completion date | December 2012 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 13 Years to 18 Years |
Eligibility |
Inclusion Criteria for Major Depressive Disorder Participants: - Participants must meet DSM-IV-TR criteria for Major Depressive Disorder, with current mood state depressed for = 2 weeks. - Participants must be females - Participants must be between the age of 13 and 18 years. - Participants must have had an adequate trial of fluoxetine, defined as a trial of = 8 weeks of treatment, with a dose of = 40mg daily for = 4 weeks. If the participant had a trial of 40mg daily and was unable to tolerate it, a dose of 20mg for = 8 weeks is acceptable; OR - Participants must have had an adequate trial of escitalopram, defined as a trial of = 8 weeks of treatment, with a dose of = 20 mg daily for = 4 weeks. If the participant had a trial of 20 mg daily and was unable to tolerate it, a dose of 10 mg for = 8 weeks is acceptable. - Participants must have a CDRS-R score of = 40 and a CGI-S score of = 4. - Participants must be able to give informed consent or assent, and where applicable, parent(s)/guardian(s) must be able to give informed permission for study participation. Inclusion Criteria for Healthy Control Participants: - Participants must be females - Participants must be between the age of 13 and 18 years. - Participants must not meet DSM-IV-TR diagnostic criteria for a psychiatric or substance abuse disorder. - Participants must be able to give informed consent or assent and, where applicable, parent(s)/guardian(s) must be able to give informed permission for study participation. Exclusion Criteria for Treatment-Resistant Major Depressive Disorder Participants: - Unstable co-morbid medical, neurological or psychiatric disorder. - Pre-existing renal disease. - Proteinuria or microalbuminuria. - Pregnant females, nursing mothers, or females of childbearing potential who are unable or unwilling to practice birth control during the study. Participants who are of child-bearing potential must have a negative urine pregnancy test before each MRI/MRS brain scan. - High risk for suicidal behavior, homicidal behavior or self-harm. - Adolescents who are unlikely to be able to comply with the study protocol. - DSM-IV-TR criteria for current substance abuse or substance dependence, with the exception of nicotine abuse or dependence. - Contraindication to MRI/MRS brain scans, such as ferromagnetic implants or claustrophobic anxiety. - Documented or suspected history of intellectual disability (Full-Scale I.Q. < 70). - History of hypersensitivity to creatine monohydrate. Exclusion Criteria for Healthy Controls: - Clinically significant psychiatric or substance abuse disorder. - Unstable medical or neurological illness. - Pregnancy, due to the unknown effects of MRI/MRS scanning on a developing fetus. - Females of childbearing potential who are unable or unwilling to practice contraception during the study. - Positive urine pregnancy test. - Contraindication to MRI/MRS scanning, such as ferromagnetic implant or claustrophobic anxiety. - Documented or suspected history of mental retardation (Full-Scale I.Q. < 70). |
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | University of Utah | Salt Lake City | Utah |
Lead Sponsor | Collaborator |
---|---|
University of Utah | AlzChem, LLC |
United States,
Kondo DG, Hellem TL, Sung YH, Kim N, Jeong EK, Delmastro KK, Shi X, Renshaw PF. Review: magnetic resonance spectroscopy studies of pediatric major depressive disorder. Depress Res Treat. 2011;2011:650450. doi: 10.1155/2011/650450. Epub 2010 Oct 4. — View Citation
Kondo DG, Sung YH, Hellem TL, Fiedler KK, Shi X, Jeong EK, Renshaw PF. Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study. J Affect Disord. 2011 Dec;13 — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean Children's Depression Rating Scale (CDRS-R) [Reference: Poznanski EO et al. Preliminary Studies of the Reliability and Validity of the Children's Depression Rating Scale. J Am Acad Child Psychiatry. 1984 Mar;23(2):191-7.] | The CDRS-R is a 17-item scale, with items ranging from 1 to 5 or 1 to 7 (possible total score from 17 to 113), rated by a clinician via interviews with the child or parent. Scores =40 are indicative of depression, whereas scores =28 is often used to define remission | 8 weeks | No |
Secondary | 31-phosphorus Magnetic Resonance Spectroscopy Phosphocreatine Metabolite | Phosphocreatine Metabolite is a phosphorylated creatine molecule that plays a role in the production of the energy in the body. Phosphocreatine (PCr) metabolite was quantified by calculating the ratio of PCr over total phosphorus resonance from 31-Phosphorus Magnetic Resonance Spectroscopy. | 8 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 |